实验方法>
细胞技术>
前沿科技及其它>Use of Tumor-Activated Hepatic Stellate Cell as a Target for the Preclinical Testing of Anti-Angiogenic Drugs Against Hepatic Tu
Use of Tumor-Activated Hepatic Stellate Cell as a Target for the Preclinical Testing of Anti-Angiogenic Drugs Against Hepatic Tu
关键词: use tumor-activated tumor来源: 互联网
The prognosis of patients with advanced liver tumors is very poor, regardless of current treatment schedules based on surgery and/or chemotherapy. Anti-angiogenic therapy represents one of the most promising target-oriented therapeutic approaches. However, because of organ-specific differentiation of liver microvasculature (1 ), the use of non organ-specific models of angiogenesis may not be adequate for screening candidate anti-angiogenic compounds, and only a few preclinical models that are able to provide clinically relevant therapeutic options are available.
推荐方法
- Xenopus Cell-Free Extracts to Study the DNA Damage Response
- Regulation of NF-B by Oncoproteins and Tumor Suppressor Proteins
- Spectral Karyotyping in Cancer Cytogenetics
- Identification of Pancreatic Cancer-Specific Cell-Surface Markers for Development of Targeting Ligands
- Anti-HMdU Autoantibodies in Human Sera as a Biomarker of Cancer Risk
- Direct Sequencing for Juvenile Polyposis Gene SMAD4/DPC4 Mutations
- Xenograft Models in Immunodeficient Animals: I. Nude Mice: Spontaneous and Experimental Metastasis Models
- HER2 FISH in Breast Cancer
- 毕式酵母表达常见问题及解析
- Expression Cloning of Human B Cell Immunoglobulins